CURE CDKL5 EPILEPSY FOUNDATION
EIN 99-1303165 · Epilepsy (G54)
What they do
In 2024, CURE5 Raised $192k to Advance Research and Therapeutic Development for CDKL5 Deficiency Disorder. The Foundation Paid $14k to Unravel Biosciences Which Provided Specialized Scientific Services Supporting Preclinical Research. Specifically, Unravel Biosciences Leveraged Its AI-driven RNA Analysis for A Rapid Drug Repurposing Screen. The Data Collected Will Be Used In Partnership With Other CURE5 Grantees. In Addition, The Foundation Designed and Launched Its Grantmaking Framework, Identified Research Collaborators, and Initiated Planning for Larger Research Grants to Be Awarded In 2025. These Activities Represent The Foundations First Year of Programmatic Operations In Pursuit of Its Exempt Purpose of Supporting Scientific Discovery and Treatments for CDKL5 Deficiency Disorder. The Principal Project Funded In 2025 Will Be An IPSC Portfolio With Boston Childrens and Building On Our Repurposing Work With Several Other Partners.
Financial picture
About this charity
- Recognized since
- January 2024
- Location
- 241 Central Park West - 8D, New York, NY 10024
- County
- New York
- In care of
- Aurelie Hasse
- Primary officer
- Aurelie Hasse, Treasurer
How to reach them
Filing and classification
- Latest tax year
- 2024
- Tax period began
- January 1, 2024
- Return type
- 990EZ
- NTEE classification
- Epilepsy (G54)
- IRS tax category
- Epilepsy
More public IRS record details
These are classification codes from the organization’s public nonprofit record.
- Subsection
- 03
- Affiliation
- 3
- Classification
- 1000
- Deductibility
- 1
- Foundation
- 15
- Organization
- 1